March 25, 2019
CEL-SCI Corporation Releases Letter to Shareholders
VIENNA, Va.–(BUSINESS WIRE)–The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual…
Pharmaceuticals, Biotechnology and Life Sciences
VIENNA, Va.–(BUSINESS WIRE)–The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual…
BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corp. (OTCQB:BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has…
–Presentations highlight company’s expertise seamlessly integrating human biology, data science and modern chemistry to advance a pipeline of investigational breakthrough…
Three poster presentations highlighting the synergistic benefits of the tetravalent bispecific (mAb2™) format compared to monospecific agents either alone or…
Completion of Phase 1 First-in-Human Trials of Cryopreserved, Off-The-Shelf haNK Cells Leads the Way to Pivotal Phase 2 Trials in Relapsed Merkel Cell Carcinoma Funding…
— Company Intends to Submit European MAA in Mid-2019 — — Webcast and Conference Call Today at 8:30 a.m. EDT…
BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt;/agt;–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development,…
CAMPBELL, Calif.–(BUSINESS WIRE)–Saama Technologies, Inc. (“Saama”), a leading clinical data analytics platform firm, announced that it has closed a $40…
— Financing to Advance Lead Anti-CD47 Antibody AO-176 in Ongoing Phase 1 Clinical Trial and Pipeline — BRISBANE, Calif. and…
Currently in a Phase 3 Pivotal Study for High-Risk Locally Advanced Cervical Cancer PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ: ADXS) (the Company),…